# Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors

> **NCT01661400** · PHASE1 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 14 (actual)

## Conditions studied

- Glioma
- Neuroectodermal Tumors, Primitive
- Wilms Tumor
- Rhabdomyosarcoma
- Sarcoma, Ewing
- Osteosarcoma
- Retinoblastoma

## Interventions

- **DRUG:** Metronomic Cyclophosphamide
- **DRUG:** Thalidomide

## Key facts

- **NCT ID:** NCT01661400
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-26
- **Primary completion:** 2023-12-27
- **Final completion:** 2023-12-27
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2024-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01661400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01661400, "Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT01661400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*